Search results for "cardiology and cardiovascular medicine"

Cystatin C levels are decreased in acute myocardial infarction

2005

Background: Cystatin C is the most abundant protease inhibitor in the plasma. Low plasma levels have been found in patients with aortic aneurysms and they seem correlated with the extension of the aortic lesions in early aneurysms detected by ultrasonography. Methods: In this study, plasma levels of cystatin C have been investigated in patients with acute myocardial infarction (AMI), unstable angina and controls. The effect on plasma levels of the G73A polymorphism of the CST3 gene has been also evaluated. Results: Patients with acute myocardial infarction showed significantly lower levels of cystatin C compared to unstable angina and controls, but levels were nearly normal in a week after …

PP.42.06

2015

Atrial fibrillation in athletes and non-athletes: evidence of different causative mechanisms

2021

P852Frequency and prognosis of type 2 myocardial infarction vs non ischemic myocardial injury: large observational study from an emergency department

2019

Abstract Background Type 2 Myocardial Infarction (T2MI), due to myocardial oxygen supply-demand mismatch in the absence of atherothrombosis and non-ischemic myocardial injury (NIMI), corresponding to troponin elevation without overt ischemia, are emerging concepts which are suspected to be common in patients hospitalized. However, their respective frequencies, risk profiles and short term prognosis in current routine clinical practice of emergency unit remains to be investigated. Methods Among the medical records of all the patients admitted from January 2014 to December 2016 in a university hospital emergency unit (n=82 543), patients with elevated troponin Ic (≥0.10μg/L) (n=4568) were sys…

C-reactive protein and family history of myocardial infarction

1999

Endovascular Treatment of Giant Visceral Aneurysms: An Overview

2021

Giant visceral aneurysms (or pseudoaneurysms) are aneurysmal lesions of the splanchnic vessels that are larger than 5 cm in diameter. As with other visceral aneurysms, treatment may be either surgical or endovascular. Both treatments face challenges given the anatomical complexity of such lesions. However, in the era of novel tools and techniques that have been developed in this field, an increasing number of giant visceral aneurysms can now be treated using endovascular approaches. The purpose of this article is to offer an overview of the most current techniques and trends in the endovascular treatment of giant visceral artery aneurysms.

A first dedicated Heart Valve Unit.

2018

Iron status measurement in routine heart failure assessment: a call for action

2017

TCT-437 Clinical outcome of coronary bifurcation management with a “fully bioresorbable” technique. Results of the multicentre BBS study

2016

Trends in Pulmonary Embolism Outcomes

2016

Acute pulmonary embolism (PE), a potentially life-threatening manifestation of venous thromboembolism (VTE), represents a major threat to the health and occasionally the life of a large number of patients worldwide. A systematic review of the published data, performed on the occasion of World